Free Trial

Coeptis Therapeutics (COEP) Stock Price, News & Analysis

Coeptis Therapeutics logo
$9.38 +0.07 (+0.75%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$9.28 -0.10 (-1.01%)
As of 03/28/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Coeptis Therapeutics Stock (NASDAQ:COEP)

Key Stats

Today's Range
$9.01
$9.66
50-Day Range
$8.50
$13.20
52-Week Range
$2.31
$13.70
Volume
12,086 shs
Average Volume
112,359 shs
Market Capitalization
$30.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Remove Ads

Coeptis Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

COEP MarketRank™: 

Coeptis Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 887th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coeptis Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coeptis Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Coeptis Therapeutics has a P/B Ratio of 19.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.24% of the float of Coeptis Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coeptis Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coeptis Therapeutics has recently increased by 18.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Coeptis Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Coeptis Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the float of Coeptis Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coeptis Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coeptis Therapeutics has recently increased by 18.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Coeptis Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Coeptis Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.88% of the stock of Coeptis Therapeutics is held by institutions.

  • Read more about Coeptis Therapeutics' insider trading history.
Receive COEP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COEP Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

COEP Stock Analysis - Frequently Asked Questions

Coeptis Therapeutics' stock was trading at $5.50 on January 1st, 2025. Since then, COEP shares have increased by 70.5% and is now trading at $9.38.
View the best growth stocks for 2025 here
.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) issued its quarterly earnings data on Friday, August, 16th. The company reported ($1.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.20.

Shares of Coeptis Therapeutics reverse split on the morning of Tuesday, December 31st 2024. The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM) and PHX Minerals (PHX).

Company Calendar

Last Earnings
8/16/2024
Today
3/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COEP
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
19.54

Miscellaneous

Free Float
2,456,000
Market Cap
$30.41 million
Optionable
Not Optionable
Beta
-0.77
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:COEP) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners